GINKGO BIOWORKS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8458 USD | -2.84% |
|
-2.96% | -49.95% |
Presenter SpeechAnna Wagner (Executives)Good afternoon. This is Anna Marie Wagner, SVP of Corp...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
0.8705
USD
Average target price
1.92
USD
Spread / Average Target
+120.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.95% | 1.74B | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- DNA Stock
- News Ginkgo Bioworks Holdings, Inc.
- Transcript : Ginkgo Bioworks Holdings, Inc., Q2 2022 Earnings Call, Aug 15, 2022
